A SINGLE DOSE OF 55MG OF BUPRENORPHINE FOR THE TREATMENT OF HEROIN DEPENDENCE: A NEW RESULT

Jamshid Ahmadi*, Firoozeh Ahmadi, Atefeh Torabi, Shahnaz Ahmadi, Farahnaz Ahmadi,

Substance Abuse Research Center, Shiraz University of Medical Sciences Shiraz; Iran

Abstract: Background: Heroin abuse is a growing problem. Objective: To assess the efficacy of a single dose of 55 mg of sublingual buprenorphine in the treatment of heroin dependence. Results: Administration of 55 mg of buprenorphine as a single dose is very helpful in the treatment of heroin dependence. Discussion: The present study clarifies that one dosage of 55 mg of buprenorphine is outstanding for the treatment of heroin dependence. This is a fascinating finding. Conclusion: We concluded that a single dose of sufficient buprenorphine could treat heroin withdrawal symptoms. This finding is a substantial addition to the literature.

Key words: Buprenorphine; Heroin withdrawals

Introduction: Food and Drug Administration (FDA) approved buprenorphine and methadone for the treatment of heroin dependency. Buprenorphine is a partial mu receptor agonist and is a safe drug such that its sublingual administration has low possibility of toxicity and overdose (1). Different investigations in the management of heroin dependence, comparing buprenorphine with methadone, illustrated that buprenorphine is more effective than methadone (2, 3, 4). In a research study, Johnson, Jaffe, and Fudala stated that 8 mg per day of sublingual buprenorphine is comparable to 60 mg of methadone regarding retention rates and opioids negative urines (5). Detoxification of buprenorphine is easier than methadone. Oral use of buprenorphine has little absorption but when administered sublingually is well absorbed, reaching 60%–70% of the plasma concentration. Comparing to other opioids buprenorphine has less physiological dependence. It can reduce the incidence of HIV and other connected disorders following opioids consumption (1, 6, 7). Heroin is an opioid mu receptor agonist. It is prepared from morphine that was earlier considered as a non-addictive derivative form of morphine (8). Opium has been used for a long time and has a long history of medical and societal approval in several parts
Ahmadi J. et al., J. Harmoniz. Res. Med. and Hlth. Sci. 2016, 3(1), 01-07

of the world, such as, North America, Europe and Asia (9, 10). Medical and psychiatric disorders are going up globally (11-29). Among mental disorders, substance connected disorders, especially opioids and stimulants induced problems have been reported as increasing globally dilemma. Now, opioids and stimulants-linked mental diseases are a progressive problem and have caused more referrals to outpatient centers, emergency wards, and psychiatric inpatients centers (30-104). At the present time we are experiencing a single dose of 55 mg of buprenorphine for the lessening and cessation of heroin withdrawal symptoms and craving. Since there are not considerable reports on this subject, therefore, our presentation may add to the literature.

We made a reliable and valid scale of measurement (32, 42) to assess the withdrawal pain and craving (based on DSM-5 criteria) for heroin withdrawal pain and craving, covering scores from 0 to 10 (0 means no pain or craving at all and 10 express harsh pain or craving and desire all the time).

Pain and Craving Scale of measurement: 0-1-2-3-4-5-6-7-8-9-10.

Patient presentment: In the current study we are going to explain a patient with heroin dependence who positively replied to a single dose of 55 mg of buprenorphine.

Our patient was a married 30 year old butcher with 3rd grade of secondary school education. He lived with his family in kavar city of Fars province in south part of Iran.

SZ began smoking opium and cannabis at age of 19. Since 5 years prior to admission he began smoking of heroin. He had few episodes of opioid induced depression in the past few years. Since 3 months prior to admission his depression became worse and developed suicidal thoughts, irritability, insomnia and aggressive behavior.

Due to depression, aggressive behavior, suicidal thoughts and agitation he was admitted in psychiatric emergency room and then was transferred to psychiatric ward.

During psychiatric interview and mental status examination he was agitated, depressed and restless. In physical and neurological examinations there were not, any significant abnormal findings. Tests for viral markers (HIV, HCV and HB Ag) were normal. Urine drug screening test was positive for morphine only.

According to precise medical, psychiatric, and substance use history and also DSM-5 criteria, he was diagnosed as “opioid induced depressive disorder and opioid (heroin) dependent.: In hospital admission, we administered venlafaxine 225 mg, sodium valproate 800 mg, chlorpromazine 200 mg, tizanidine 8 mg and ibuprofen 1200 mg per day for the treatment of depression, agitation and insomnia.

On the first and second days of admission SZ complained of severe withdrawal pain and severe opioid craving, hence in the afternoon of 2nd day of admission we administered buprenorphine 55 mg as a single dose only. Out of 10, the mean scores of heroin craving for 11 days of admission were 7.5, 5.3, 0.3, 1, 1, 1.3, 0, 0, 1, 0.3, and 0 respectively.

With reference to the close monitoring, precise measurement and interview (3 times a day) for heroin withdrawal craving, SZ reported a reducing level of craving after administration of a single dose of 55 mg of sublingual buprenorphine.

Our patient was discharged without any significant heroin withdrawal symptoms after 11 days of hospital admission.

Discussion

According to the current Iranian drug program if anybody is found to be consuming illicit substances or drugs, such as, hashish, marijuana, ecstasy, methamphetamine, hallucinogens, cocaine, alcohol, opium and heroin (tobacco products are legal), they must be referred to treatment centers such as psychiatric hospitals or private clinics to be treated.

In Iran, opioids dependents are usually detoxified and treated with clonidine, methadone and sometimes with buprenorphine.

This report indicates that administration of 55 mg of sublingual buprenorphine as a single dose is very effective in the treatment of heroin withdrawal symptoms. Therefore, this study could be a substantial addition to the literature.
Conclusions: We reach to this conclusion that a single dose of 55 mg of sublingual buprenorphine could successfully treat heroin withdrawal symptoms. It appears that buprenorphine is very effective in the treatment of heroin dependence. Overall, 55 mg of buprenorphine as a single dose is much better than traditional methods, such as abrupt discontinuation or stepwise reduction in the heroin dosage.

Acknowledgement: None to be declared.

Conflict of interests: Nil

References:
1- Jasinski, D. R., Pevnick, J. S., & Griffith, J. D. (1978). Human pharmacology and abuse potential of the analgesic buprenophine: a potential agent for treating narcotic addiction. Archives of General Psychiatry, 35, 501–516.
2- Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S. Jr., Kintaudi, P., Wesson, D. R., McNicholas, L., Tusel, D. J., Malkerneker, U., Renner, J. A. Jr., Santos, E., Casadonte, P., Fye, C., Stine, S., Wang, R. I., & Segal, D. (1998). Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction, 93, 475–486.
3- Ling, W., Rawson, R. A., & Compton, M. A. (1994). Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine. Journal of Psychoactive Drugs, 26, 119–128.
4- Strain, E. C., Stitzer, M. L., Liebson, I. A., & Bigelow, G. E. (1994). Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry, 151, 1025–1030.
5- Johnson, R. E., Jaffe, J. H., & Fudala, P. J. (1992). A controlled trial of buprenorphine treatment for opioid dependence. Journal of the American Medical Association, 267, 2750–2755.
6- Lewis, J. W. (1985). Buprenorphine. Drug and Alcohol Dependence, 14, 363–372.
7- Jasinski, D. R., Fudala, P. J., & Johnson, R. E. (1989). Sublingual versus subcutaneous buprenorphine in opiate abusers. Clinical Pharmacology and Therapeutics, 45, 513–519.
8- Sadock, B., Sadock, V., Ruiz, P. (Editors) Kaplan &Sadock’S Synopsis of Psychiatry: LippinottWilliams and Wilkins, Philadelphia (USA), 2015.
9- Brian, J. (1994) Opium and infant-sedation in 19th century England, Health Visitor, 76, 165-166.
10- Jonnes, J. (1995) The rise of the modern addict, American Journal of public Health, 85, 1157-1162.
11- Gill D, Ahmadi J, Pridmore S, Suicide and Gambling on the Public Record. MJP. 2014; 2 (1): 81-88
12- Ahmadi J, Kamel M, Ahmed MG, Bayoumi FA, Moneenum A. Mental Health of Dubai Medical College Students. Iran J Psychiatry Behave Sci. 2012; 6(2): 79-83.
13- Ahmadi J, Kamel M, Ahmed MG, Bayoumi FA, Moneenum AA. Dubai Medical College students’ scores on the Beck Depression Inventory. Iranian Red Crescent Journal (IRCMJ). 2008; 10(3):169-172
14- Pridmore S, McInerney G, Ahmadi, Rybak M. Enlarged Virchow-Robin Spaces in a psychotic woman, Journal of Psychiatric Intensive Care (2007) 3: 49-54
15- Pridmore S, Robinson J, Ahmadi J. Suicide for scrutinizers. Australas Psychiatry. 2007 Jun; 15 (3): 247-8.
16- Ghanizadeh A, Kianpoor M, Rezaei M, Rezaei H, Moini R, Aghakhani K, Ahmadi J, Moeini SR. Sleep patterns and habits in high school Students in Iran. Ann Gen Psychiatry. 2008 Mar 13; 7:5.
17- Ghanizadeh A, Arkan N, Mohammadi MR, Ghanizadeh-Zarchi MA, Ahmadi J. Frequency of and barriers to utilization of mental health services in an Iranian population. East Mediterr Health J. 2008 Mar-Apr; 14(2):438-46
18- Pridmore S, Ahmadi J, Two cases of ‘Type 3’ suicide. Australasian Psychiatry. 2010, Vol 18, No 5: 426-430
19- Pridmore S, Brune M, Ahmadi J, Dale J. Echopraxia in schizophrenia: Possible mechanisms. Aust N Z J Psychiatry. 2008, Jul; 42(7):565-71.
20- Pridmore S, Ahmadi J, Reddy A. Suicide in the absence of mental disorder.
21- Pridmore S, Ahmadi J, Majeed ZA. Suicide in Old Norse and Finnish Folk stories. Australasian Psychiatry. 2011, Vol 19, No 4:322-324
22- Pridmore S, Ahmadi J, Usage of download of psychiatry by Muslim Countries. Bulletin of clinical psychopharmacology. 2011, Vol 21, No 2: 174
23- Mani A, Dastgheib SA, Chanoor A, Khalili HA, Ahmadzadeh L, Ahmadi J, Sleep Quality among Patients with Mild Traumatic Brain Injury: A Cross-Sectional Study. Bull Emerg Trauma. 2015; 3(3): 93-96.
24- Pridmore S, Ahmadi J; Psalm 137 and Middle Cerebral Artery Infarction; ASEAN Journal of Psychiatry, 2015; 16 (2).
25- Pridmore S, Ahmadi J. Book reviews. Aust NZ J Psychiatry, 39(3): 205-6, 2005.
26- Pridmore S, Ahmadi J, Evenhuis M. Suicide for scrutinizers. Psychiatry. 2006 Dec; 14(4):359-64.
27- Ahmadi J, Ahmadi N, Soltani F, Bayat F. Gender differences in depression Scores of Iranian and German medical students. Iran J Psychiatry Behav Sci  2014; 8(4): 70-73
28- Mackay-Smith M, Ahmadi J; Pridmore S, Suicide in Shooting Galleries ASEAN Journal of Psychiatry, Vol. 16 (1), January - June 2015: 50-56
29- Khademalhosseini Z, Ahmadi J, Khademalhosseini M, Prevalence of Smoking, and its Relationship with Depression, and Anxiety in a Sample of Iranian High School Students. Enliven: Pharmacovigil Drug Saf. 2015; 1(1):005.
30- Ahmadi J, Ghafoori M, Rahimi S, Management of heroin addiction with baclofen and clonidine. Int J Res Rep 2015; 1(1):6-10.
31- Ahmadi J, Sahraian A, Shariati S, Homicidal patient with major depressive disorder companion with opium dependence: A new arcade. Int J Res Rep 2015; 1(1):1-5
32- Ahmadi, J. Heroin Dependency Treatment: A New Approach. J Addict Depend 2015; 1(2): 1-3.
33- Ahmadi J Hashish-Induced Olfactory Hallucination: A Novel Finding. J Psychiatry, 2015; 18:330. doi:10.4172/2378-5756.1000330
34- Ahmadi, J. Excellent Outcome of Psychosis Induced by Methamphetamine Intoxication after 20 Sessions of Electro Convulsive Therapy. J Addict Depend 2015 1(2): 1- 2.
35- Ahmadi J, Ekramzadeh S, Pridmore S, Remission of Methamphetamine-Induced Withdrawal Delirium and Craving after Electroconvulsive Therapy Iran J Psychiatry Behav Sci. 2015 December; 9(4):e1793.
36- Ahmadi J, Sahraian A, Dastgheib SA, Moghimi E, Bazrafshan A, Treatment of heroin abuse.Sch. Acad. J. Biosci., 2015; 3(11):966-968
37- Ahmadi J, Sahraian A, Dastgheib SA, Mani A, Mowl a, Ahm adzadeh L, ECT and methamphetamine psychosis: IJMPS., 2015; 7(1): 51-53
38- Ahmadi J Tramadol Dependency Treatment: A New Approach. J Addict Med Ther Sci., 2015; 2(1): 001-03.
39- Ahmadi J, Dehghanian I, Razeghian Jahromi L. Poly substance induced psychosis Sch. J. App. Med. Sci., 2015; 3(7D):2693-2695
40- Ahmadi J, Dehghanian I, Razeghian Jahromi L, Substance induced disorder. Sch. J. App. Med. Sci., 2015; 3(7D):2700-2703
41- Ahmadi J, Pridmore S, Ekramzadeh S, Successful Use Of Electro Convulsive nTherapy in The Management Of Methamphetamine Induced Psychosis With Onset During Intoxication. J Addict & Depend, 2015; 1, 1-3
42- Ahmadi J. The Effect of Buprenorphine and Bupropion in the Treatment of Methamphetamine Dependency and Craving. Br J Med & Med Res 2015; 10 (2): 1-4
43- Ahmadi J, Sahraian A, Dastgheib SA, Mowl a, Ahm adzadeh L, Management of Methamphetamine-Induced Psychosis by 8 sessions of ECT Sch. J. App.Med. Sci., 2015; 3 (3H):1565-1566.
44- Ahmadi J, Amiri A, Ghanizadeh A, Khademalhosseini M, Khademalhosseini Z, Gholami Z et al . Prevalence of Addiction to the Internet, Computer Games, DVD, and Video
and Its Relationship to Anxiety and Depression in a Sample of Iranian High School Students. Iran J Psychiatry Behav Sci. 2014; 8 (2):75-80
45- Ahmadi J, Soltani F, Tabatabae F, et al., Substance Use Disorders in Patients With Lung or Heart Diseases. Sch. J. App. Med. Sci., 2014; 2(1A):111-120
46- Ahmadi J, Sharifi M Lifetime and Current Prevalence of Tobacco Smoking. J. Addict Res Ther 2013; 4: 145. doi:10.4172/2155-6105.1000145
47- Ahmadi J, Ahmed MG. Dubai Medical College Students’ Attitudes towards Substance Use. J Addict Res Ther (2013) S6: 005. doi:10.4172/2155-6105.S6-48- Ahmadi J, Keshhtkar M, Pridmore S. Methamphetamine Induced Synesthesia: A Case Report. Am J Addict. 2011; 20: 306
49- Ahmadi J, Naghshvarian M, Afshari R. Opioid abuse in male population referred for mandatory Urine Opioid Screen before marriage in Shiraz-Iran. Iranian J Psychiatry Behav Sci. 2011; 5(2): 126-30.
50- Ahmadi J, Kampman K, Osline DM. et al, Predictors of Treatment Outcome in Outpatient Cocaine and Alcohol Dependence Treatment. Am J Addict. 2009; 18:81–86
51- Ahmadi J, Benrazi L, Babaebeigi M, Ghanizadeh A, Ghanizadeh M, Pridmore S. Substance use in a sample of medical patients. J Psychoactive Drugs. 2008 Sep; 40(3):315-9.
52- Ahmadi J, Kampman K, Dackis C, Sparkman T, Pettinati H Cocaine withdrawal symptoms identify Type B cocaine-dependent patients. Am J Addict. 2008; 17 (1): 60-64.
53- Ahmadi J, Pridmore S, Alimi, A, et al., Epidemiology of Opium Use in the General Population. Am. J. Drug and Alcohol Abuse, 2007; 33: 483–491.
54- Ahmadi J, Kampman K, Dackis C. Outcome predictors in cocaine dependence treatment trials. Am J Addict. 2006 Nov-Dec; 15 (6):434-9.
55- Tabei SZ, Heydari ST, Mehrabani D, Shamsina SJ, Ahmadi J, Firouzi SM. Current substance use in patients with gastric cancer in Southern Iran. J Can Res Ther 2006; 2:182-185
55- Ahmadi J, Fallahzadeh H, Salimi A, Rahimian M, Salehi V, Khaghani M, Babaebeigi M. Analysis of opium use by students of medical sciences. J Clin Nurs. 2006 Apr; 15(4):379-86.
56- Ahmadi J, Tabatabae F, Gozin Z. Physical trauma and substance abuse: a comparative study on substance abuse in patients with physical trauma versus general population. J Addict Dis. 2006; 25(1):51-63.
57- Ahmadi, J., Ahmadi, M., Pridmore, S., et al., Substance Use Disorders in Rheumatic Patients. German J Psychiatry.2005; 5 (8): 66-9.
58- Ahmadi, J., Menzies, P., Maany, I., et al., Pattern of cocaine and heroin abuse in a sample of Iranian general population. German J Psychiatry. 8 (1): 1-4. 2005
59- Ahmadi, J., Farrashbandi, H., Menzies, P et al., Prevalence of mood and anxiety disorders in a sample of Iranian outpatient opioid addicts. German J Psychiatry. 8 (1): 5-7. 2005.
60- Ahmadi, J., Farrashbandi, H., Majdi, B., et al., Subsance-induced anxiety disorder in opioid dependents. Addictive Disorders & Their Treatments.1-4, 2005.
61- Ahmadi, J., Babae-Beigi, M., Alishahi, M., Maany, I., Hidari, T. Twelve-month maintenance treatment of opium-dependent patients. J Subst Abuse Treat. 26(1): 363-366, 2004.
62- Ahmadi J, Babaebeigi M, Maany I, et al. Naltrexone for alcohol dependent patients Irish J Med Science, 173 (1): 34-37, 2004.
63- Ahmadi, J., Majdi, B., Mahdavi, S., Mohaghegh, M., Mood disorders in opioid dependent patients. J.Affective Disorders. 82: 139-42, 2004.
64- Ahmadi, J., Farrashbandi, H., Moosavinasab, M, et al., Treatment of heroin dependence. German J Psychiatry. 7 (2): 1-5. 2004.
65- Ahmadi, J., Pridmor, S., Fallahzadeh, M. Neurotic scores in medical students. German J Psychiatry. 7: 51-5. 2004.
66- Ahmadi, J., Maharlooy, N., Alishahi, M. Substance abuse: prevalence in a sample of nursing students. J Clin Nurs. 13(1): 60-4, 2004.
67- Ahmadi, J., Alavi, M., Alishahi, M. Substance Use Disorders in a Sample of Iranian Secondary School Students. Social Indicators Research. 65(3): 355-360, 2004.
68- Pridmore, S., Skerrit, P., Ahmadi, J. Why do doctors dislike treating people with somatoform disorder? Australasian Psychiatry. 12 (2): 134-138, 2004.
69- Ahmadi, J., Toobaee, S., Alishahi, M. Depression in nursing students. J Clin Nurs. 13(1): 124. 2004.
70- Ahmadi, J., Ahmadi, K., Ohaeri, J. Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study. Eur J Clin Invest. Sep; 33(9): 824-9, 2003.
71- Ahmadi, J., Rayisi, T., Alishahi, M. Analysis of substance use by primary school students. German J Psychiatry, 3:56-59, 2003.
72- Ahmadi, J., Alavi, M., Alishahi, M. Twenty-four week maintenance treatment of heroin-dependent outpatients with buprenorphine. J Subst Use Treat. Apr; 24(3): 251-5, 2003.
73- Ahmadi, J., Etminan, H., Javanmardi, H. Reasons for cessation of opiate use among Iranian opioids dependants. Addictive Disorders & Their Treatment. 2(1): 9-12, 2003.
74- Ahmadi, J., Rayisi, T., Alishahi, M. Analysis of substance use by primary school students. German J Psychiatry. 3:56-59. 2003.
75- Ahmadi, J., Ashkani, H., Ahmadi, M., Ahmadi, N. Twenty-four week maintenance treatment of cigarette smoking with nicotine gum, clonidine and naltrexone. J Subst Abuse Treat. Apr; 24(3): 251-5, 2003.
76- Ahmadi, J., Ahmadi, M., Twelve-month maintenance treatment of heroin-dependent outpatients with buprenorphine. J Subst Use. April 8(1): 39-41, 2003.
77- Ahmadi, J., Sharifi, M. Cannabis abuse in Iran. Irish J Med Sci. Jan-Mar; 172(1): 46, 2003.
78- Ahmadi, J., Arabi, H., Mansouriy, Y. Prevalence of substance use among offspring of opioid addicts. Addict Behav. Apr; 28(3): 591-5, 2003.
79- Ahmadi, J., Motamed, F. Treatment success rate among Iranian opioid dependents. Subst Use Misuse. Jan; 38(1): 151-63, 2003.
80- Ahmadi, J., Hasani, M. Prevalence of substance use among Iranian high school students. Addict Behav. Mar; 28(2): 375-9, 2003.
81- Ahmadi, J., Maany, I., Ahmadi, M. Treatment of Intravenous Buprenorphine Dependence: A Randomized Open Clinical Trial. German J Psychiatry. 6:23-29, 2003.
82- Ahmadi, J., Javadan, A. Assessing substance use among Iranian health care students. European J Psychiatry. 16(3): 174-177, 2002.
83- Ahmadi, J., Bahrami, N. Buprenorphine treatment of opium-dependent outpatients seeking treatment in Iran. J Subst Abuse Treat. Dec; 23(4): 415-7, 2002.
84- Ahmadi, J., Samavati, F., Sayyad, M., Ghanizadeh, A. Various types of exercise and scores on the Beck Depression Inventory. Psychol Rep. Jun; 90(3 Pt 1): 821-2, 2002.
85- Ahmadi, J., Yazdanfar, F. Substance use among Iranian university students. The International Journal of Drug Policy. 13(6): 507-508, 2002.
86- Ahmadi, J. A randomized, clinical trial of buprenorphine maintenance treatment for Iranian patients with opioid dependency. Addictive Disorders & Their Treatments. 1(1): 24-27, 2002.
87- Ahmadi, J., Benrazavi, L. Substance use among Iranian physical patients. The International Journal of Drug Policy. 13(6): 505-506, 2002.
88- Ahmadi, J., Ostovan, M. Substance use among Iranian male students. The International Journal of Drug Policy. 13(6): 511-512, 2002.
89- Ahmadi, J. Buprenorphine maintenance treatment of heroin dependence: the first experience from Iran. J Subst Abuse Treat. Apr; 22(3): 157-9, 2002.
90- Ahmadi, J., Benrazavi, L. Substance use among Iranian nephrologic patients. Am J Nephrol. Jan-Feb; 22(1):11-3, 2002.
91- Ahmadi, J., Ahmadi, N. A Double Blind Placebo-Controlled Study of Naltrexone in the...
Treatment of Alcohol Dependence. German J Psychiatry 2002; 5(4): 85-9, 2002.

92- Ahmadi, J., Benrazavi, L. Substance use among Iranian surgical patients. The International Journal of Drug Policy 13(6) 509-510, 2002.

93- Ahmadi, J. A controlled trial of buprenorphine treatment for opium dependence: the first experience from Iran. Drug Alcohol Depend. Apr 1; 66(2): 111-4, 2002.

94- Ahmadi, J., Benrazavi, L. Substance use among Iranian cardiovascular patients. Eur J Med Res. Feb 21; 7(2): 89-92, 2002.

95- Ahmadi, J., Benrazavi, L, Ghanizadeh, A. Substance abuse among contemporary Iranian medical students and medical patients. J Nerv Ment Dis. Dec; 189(12): 860-1, 2001.

96- Ahmadi, J., Fakoor, A, Pezeshkian, P., Khoshnood, R., Malekpour, A. Substance use among Iranian psychiatric inpatients. Psychol Rep. Oct; 89(2): 363-5, 2001.

97- Ahmadi, J., Sharifi, M. Prevalence of alcohol use disorders. J Subst Use. 7(4): 251 – 254, 2002.

98- Ahmadi, J., Khalili, H., Jooybar, R., Namazi, N., Mohammadagaei, P. Prevalence of cigarette smoking in Iran. Psychol Rep. Oct; 89(2): 339-41, 2001.

99- Ahmadi, J., Ghanizadeh, A. Current substance use among Iranian medical students. Indian J Psychiatry. 43(2): 157-161, 2001.

100- Ghanizadeh, A., Ahmadi, J. The MMPI Profile of Opiate Addicts of Iran: Evidence from Shiraz. Annals of Saudi Medicine 20, 3-4:334-5, 2000.

101- Ahmadi, J., Ghanizadeh, A. Motivations for use of opiates among addicts seeking treatment in Shiraz. Psychol Rep. Dec; 87(3 Pt 2): 1158-64, 2000.

102- Ahmadi, J., Khalili, H., Jooybar, R., Namazi, N., Aghaei, P.M. Cigarette smoking among Iranian medical students, resident physicians and attending physicians. Eur J Med Res. Sep 28; 6(9): 406-8, 2001.

103- Ahmadi, J., Sahraian A, Shariati S, Delusional disorder joined with opium dependence Sch. J. App. Med. Sci., 2015; 3(9D):3387-3390

104- Ahmadi J, Dastgheib SA, Mowla A, Ahmadzadeh L, Bazrafshan A, Moghimi Sarani EM, Treatment of Methamphetamine Induced Persistent Psychosis. J Add Pre Med (2016) 1(1): 103.